OlympiAD trial, a phase III randomized study, investigated the efficacy of olaparib in patients with metastatic, HER2 negative BC who were carriers of deleterious germline BRCA1 and BRCA2 mutations. The gene discussed is ERBB2; the disease is breast cancer.